Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Prudential PLC — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Prudential PLC trades at $28.65 (market cap $35.11B). The key difference: Prudential PLC is far larger — about 4.4× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Prudential PLC pays a 1.86% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | PUK | |
|---|---|---|
Market Cap | $8.04B | $35.11B |
Sector | Health | Financials |
52-Week High | $339.75 | $33.61 |
52-Week Low | $241.71 | $24.65 |
Enterprise Value | $7.85B | $36.55B |
Dividend Yield | — | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Prudential (PUK) trades at $28.40, up 0.96% with bullish technical signals from moving averages. The stock shows strong fundamentals with a P/E of 9.25, net income margin of 14.52%, and ROE of 21.15%. Recent earnings beat expectations in Q2 and Q4 2025, while analyst consensus leans bullish with 50% buy ratings. Positive news includes JP Morgan's catalyst watch ahead of August results and strategic expansion in India.
Outlook remains positive with improving cash flow trends and debt reduction. Key opportunities include Asia growth exposure and strong profitability metrics. Risks include China regulatory uncertainty and Japan sales suspension impacts. The stock presents value with attractive valuation multiples and analyst support for upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
